OHE Publications

OHE releases a number of publications throughout the year, authored by OHE team members and/or outside experts. All are free for download as pdf files; hard copies of some publications are available upon request.

A description of the OHE publications categories.


 

Cubi-Molla, P., Mott, D., Shah, K., Herdman, M., Summers, Y. and Devlin, N.

Consulting Report
June 2018

Cancer survival rates have improved dramatically in recent decades due in part to pharmaceutical advances, with a growing range of increasingly effective and targeted medicines being developed, such as immunotherapies. In the economic modelling of such treatments, the question arises of which utilities should be assigned to patients who show a long-term, durable response.

In recent critiques of economic models in this area by the National Institute for Health and Care Excellence (NICE), the idea that long-term cancer survivors (LTCS) who have received such treatments could report quality of life (QoL) scores which are similar to, or higher than, those of equivalent general population samples has not been viewed as credible. This literature review examines whether there is evidence to support the assumption that the QoL of LTCS can be similar to that of age/sex-matched population samples.

This study was funded by Roche Products Ltd.

Karlsberg Schaffer, S., West, P., Towse, A., Henshall, C., Mestre-Ferrandiz, J., Masterson, R., and Fischer, A.

Briefing
May 2017

Antimicrobial resistance (AMR) occurs when microorganisms such as bacteria, viruses, fungi and parasites change in ways that render the medications used to cure the infections they cause ineffective.

Hampson, G., Towse, A. and Henshall, C.

Briefing
April 2017

The 2015 meeting of the HTAi Asia Policy Forum meeting was held in Singapore, 29th -30th October 2015. The topic of the meeting was: How can HTA meet the needs of health system and government decision makers? This report represents the background paper for the meeting, as developed by OHE.

Cole, A., Marsden, G., Devlin, N., Grainger, D., Lee, E.K. and Oortwijn, W.

Briefing
August 2016

This report provides a detailed summary of a panel session which took place at the HTAi 2016 annual meeting in Tokyo. The panel session was entitled "New Age Decision Making in HTA: Is It Applicable in Asia?". To open the session, David Grainger (Eli Lilly & Company) provided an overview of the session, offering useful background information on the topic. 

Hernandez-Villafuerte, K., Li, R., Towse, A. and Chalkidou, K.

Occasional Paper
April 2015

This mapping of priority-setting considers factors such as existence of HTA institutions and commitment to UHC (Brazil, Chile, Colombia, Mexico, Uruguay, Ghana, Kenya, Malawi, South Africa, Uganda, China, India, Indonesia, Myanmar, Philippines, Thailand and Vietnam).

Towse, A.

Occasional Paper
December 2014

This OHE Occasional Paper by Adrian Towse discusses Professor Bengt Jönsson’s observations in a 2011 publication about the role of relative effectiveness research (RE) in the European medicines market and how this could lead to improved efficiency in the development of medicines, the pricing and use of medicines, and of health systems.

Rejon-Parrilla, J.C., Hernandez-Villafuerte, K., Shah, K., Mestre-Ferrandiz, J., Garrison, L. and Towse, A.

Consulting Report
May 2014

This report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. Included are the ten cancer drugs approved by the EMA during 2003–2005. Decisions by France’s HAS, NICE and Aetna in the US are analysed.

Mestre-Ferrandiz, J. and Towse, A.

Briefing
April 2014

This Briefing summarises the results of a roundtable convened by OHE to discuss using HTA to assess biosimilars – including which methods are most appropriate in specific situations. Participating were ten experts: leading academics and representatives from the UK medicines regulatory agency, the three UK HTA entities, and the UK industry trade association. Background for discussion at the meeting included an OHE literature review and ABPI’s 2013 position paper on biosimilar medicines.

Pages